VOR BIOPHARMA INC.
100 Cambridgepark Drive, Suite 101
Cambridge, MA 02140
December 16, 2022
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Jason Drory | |
| Re: | Vor Biopharma Inc. | |
| Registration Statement on Form S-3 (File No. 333-268798) | ||
| Request for Acceleration of Effective Date | ||
| Acceleration Request | ||
| Requested Date: December 20, 2022 | ||
| Requested Time: 4:00 p.m. Eastern Time | ||
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-268798) (the “Registration Statement”) to become effective on December 20, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Katie Kazem at (703) 456-8043.
[Signature page follows]
| Very truly yours, | ||
| Vor Biopharma Inc. | ||
| By: | /s/ Robert Ang | |
| Robert Ang | ||
| Chief Executive Officer and Director | ||
| cc: | ||
| Robert Ang, Vor Biopharma Inc. | ||
| Nathan Jorgensen, Vor Biopharma Inc. Divakar Gupta, Cooley LLP Katie Kazem, Cooley LLP |
Signature Page to Company Acceleration Request – S-3